Long follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial (CRUK/07/033) confirms the safety of both de-escalation and intensification of chemotherapy
Luminari, S. Fossa, A. Trotman, J. Molin, D. D'Amore, F. A. Enblad, G. Berkahn, L. Barrington, S. F. Radford, John A Federico, M.
Luminari, S.
Fossa, A.
Trotman, J.
Molin, D.
D'Amore, F. A.
Enblad, G.
Berkahn, L.
Barrington, S. F.
Radford, John A
Federico, M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Luminari S, Fossa A, Trotman J, Molin D, D'Amore FA, Enblad G, et al. Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200315.